Orexigen Therapeutics, Inc. (OREX) Reports In-Line Q2 Loss of 21c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Orexigen Therapeutics, Inc. (OREX) Reports In-Line Q2 Loss of 21c/Share

BofA/Merrill Lynch Remains Bullish on Orexigen (OREX) Ahead of Sept PDUFA Amid Update; PT Trimmed to $10

August 7, 2014 3:38 PM EDT

Shares of Orexigen Therapeutics (NASDAQ: OREX) are modestly higher following encouraging comments from management about activities it is conducting ahead of the September 11thPDUFA for its weight loss drug NB32 (Contrave).

BofA/Merrill Lynch analyst Steve Byrne highlights that Orexigen has been working... More